Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gastrointestinal 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Neoplasms 1Laryngeal Diseases 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1

Interventions

Cetuximab 4pembrolizumab 3Trastuzumab 3Radiotherapy 3Erlotinib Hydrochloride 3Tomography, X-Ray Computed 2Magnetic Resonance Spectroscopy 2Fluorodeoxyglucose F18 2Docetaxel 2Biopsy 2ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1tipifarnib 1sargramostim 1sapanisertib 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1oblimersen 1nanocis 1mercaptoundecahydrododecaborate 1larotrectinib 1ipatasertib 1fluoromisonidazole 1erythromycin propionate-N-acetylcysteinate 1erdafitinib 1entinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rectal Neoplasms × capmatinib × Head & Neck × Clear all
NCT02205398 2019-01-22

Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy

Novartis

Phase 1 Terminated
13 enrolled
GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Laryngeal Diseases, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡